bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
C3

Order Name:
B1C (C3)

 
Useful For:
Assessing disease activity in systemic lupus erythematosus (SLE). Investigating an undetectable total complement (CH50) level
 
Methodology:
Immunoturbidimetric
 
AliasesName:
B1C
C3
C3 (3rd Component of Complement), Serum
C3 (Third Component of Complement), Serum
C3 COMP, S
Complement C3
 
 
 
Test Code:
C3

Order Name:
B1C (C3)

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: 4+ reject
 
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum Refrigerated: 2oC to 8oC 2 days
Frozen: -20oC 8 days
 
 
 
Test Code:
C3

Order Name:
B1C (C3)

 
Method detail:
Immunoturbidimetric
 
Schedule:
Tested daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 1.5 hours (90 mins)
 
Performing Location:
Chemistry, Laboratory Department Tel. 13224
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
C3

Order Name:
B1C (C3)

 
 
Clinical Information:
All complement proteins are acute phase reactants and rise rapidly in concentrations during inflammatory episodes. Conversely, the rates of complement protein catabolism may greatly increase in various autoimmune diseases. Because complement component determinations represent a static measurement of the net concentrations that result from a dynamic balance between component synthesis and catabolism, serial sample quantitations are more clinically useful.

In most disease states, complement functions “normally” in producing inflammation and tissue damage. When complement plays a role in the development of a disease, it is often due to activation by an “abnormal” antibody, immune complex, or foreign material.

Increased C3 levels are associated with acute phase reaction, rheumatic disease, viral hepatitis, myocardial infarction, cancer, diabetes, pregnancy, sarcoidosis, amyloidosis, thyroiditis, inflammatory bowel disease, typhoid fever, and pneumococcal pneumonia. The magnitude of C3 increase is rarely more than two-fold and may mask decreases in levels due to concurrent consumption.

Decreased levels of C3 occur in individuals with congenital deficiency or immunologic diseases (where complement is consumed at an increased rate). C3 and/or complement C4 (C4) levels may be decreased in cases of: systemic lupus erythematosus (SLE) (especially with lupus nephritis), acute and chronic hypocomplementemic nephritis, infective endocarditis, disseminated intravascular coagulation (DIC) (especially with hemolytic uremic syndrome form), and partial lipodystrophy (with associated nephritis-like activity in serum). Cases of hereditary C3 deficiency, while rare, are characterized clinically by recurrent infection and by immune complex disease, in particular, membranoproliferative glomerulonephritis. The central role of C3 in both classical and alternate pathways, results in C3 deficient patients being at risk for especially severe infections by encapsulated bacteria such as S. pneumoniae, H. influenzae, and N. meningitidis. Bacteremia, sinopulmonary infections, meningitis, paronychia, and impetigo may occur. Deficient C3 levels have also been found in cases of uremia, chronic liver diseases, anorexia nervosa, and celiac disease.
 
Reference Value:
Test: B1C (C3)
 
Test Reference Value Unit
Male 82 - 185 mg/dL
Female 83 - 193 mg/dL
 
Interpretation:
A decrease in C3 levels to the abnormal range is consistent with disease activation in systemic lupus erythematosus (SLE).
 
Clinical Reference:
1. Manufacturer’s reagent package insert, Architect® Complement 3,
    ABBOTT Laboratories, Diagnostic Division, Abbott Park IL 60064 USA, November 2015.
2. http://www.mayomedicallaboratories.com (Retrieved: 01 Jan 2019)